The Party Should Not Last That Long.

Too much food, too much wine, and too many friends. You'll pay the price tomorrow; you shouldn't have let the party last so long. This analogy seems apt with respect to our new understanding of atrial fibrillation (AF) and approaches to AF. The keys to understanding recent advances in the management of AF and improving outcomes on therapies are an appreciation that: (1) AF is often a progressive disorder; (2) its progression is related to the degree of atrial myopathy that is present; (3) atrial myopathy is a consequence of the effects of underlying comorbidities as well as the effect of AF itself (tachycardic effects on the atria); (4) adverse outcomes can be a consequence of AF, the underlying atrial myopathy, as well as direct consequences of any comorbidities present; (5) rhythm control of AF early in its course as well as early and optimal treatment of underlying comorbidities have been associated with improved outcomes (eg, lower mortality, lesser thromboembolism, lesser heart failure, fewer hospitalizations) in recent trials; (6) therapies not available 2 decades ago during the rate- versus rhythm-control trials have played a role in the new treatment approaches and make the old idea that rate control is as good as rhythm control somewhat obsolescent; and (7) these now indicate that optimal and early rhythm control and comorbidity treatment provide the best results for AF patients.